EKF Diagnostics Investor Announcements
EKF Diagnostics Holdings plc is an in-vitro diagnostics (IVD) business. The Company is engaged in the designing, development, manufacture and selling of diagnostic analyzers, reagents and ancillary products. This activity takes place across several geographical locations which include the United Kingdom, United States of America, Germany, Poland and Russia.
EKF Diagnostics announces that RenalytixAI will be admitted to trading on AIM on 6 November 2018.
The Company is pleased to announce the results of the restricted offer made to its shareholders by Renalytix AI plc.
Following the release of the Company’s announcement on 22 October 2018, the Company provides the below update in relation to its planned distribution timetable.
Shareholder approval was received for a distribution in specie of shares in Renalytix AI plc to the Company's shareholders.
EKF Diagnostics announces the resolution from the General Meeting held earlier today.
EKF Diagnostics announces a briefing for all investors to provide details of the successful fundraising and proposed AIM admission of Renalytix AI plc.
Today the Company announced a successful, conditional equity fundraising by its spin-out business, Renalytix AI plc.
EKF Diagnostics confirms equity fundraising.
EKF Diagnostics Holdings plc announces that a general meeting of the Company will be held on 19 October 2018.
EKF Diagnostics Holdings plc announces its unaudited interim results for the six months ended 30 June 2018.